Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $12.28 billion. The enterprise value is $12.63 billion.
Important Dates
The next estimated earnings date is Tuesday, November 4, 2025, after market close.
| Earnings Date | Nov 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 61.10 million shares outstanding. The number of shares has increased by 4.73% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 61.10M |
| Shares Change (YoY) | +4.73% |
| Shares Change (QoQ) | +6.49% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 79.12% |
| Float | 60.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 174.78 |
| PS Ratio | 20.73 |
| Forward PS | 11.62 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 21.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.02
| Current Ratio | 1.02 |
| Quick Ratio | 0.66 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.99 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -17.17% |
| Return on Invested Capital (ROIC) | -33.13% |
| Return on Capital Employed (ROCE) | -165.81% |
| Revenue Per Employee | $566,698 |
| Profits Per Employee | -$313,116 |
| Employee Count | 1,017 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 0.27 |
Taxes
In the past 12 months, Ascendis Pharma has paid $8.24 million in taxes.
| Income Tax | 8.24M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.43% in the last 52 weeks. The beta is 0.45, so Ascendis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +60.43% |
| 50-Day Moving Average | 201.09 |
| 200-Day Moving Average | 170.97 |
| Relative Strength Index (RSI) | 46.37 |
| Average Volume (20 Days) | 411,587 |
Short Selling Information
| Short Interest | 3.42M |
| Short Previous Month | 2.56M |
| Short % of Shares Out | 6.79% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.35 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $576.33 million and -$318.44 million in losses. Loss per share was -$5.36.
| Revenue | 576.33M |
| Gross Profit | 489.21M |
| Operating Income | -297.74M |
| Pretax Income | -310.20M |
| Net Income | -318.44M |
| EBITDA | -291.96M |
| EBIT | -297.74M |
| Loss Per Share | -$5.36 |
Full Income StatementBalance Sheet
The company has $580.21 million in cash and $930.75 million in debt, giving a net cash position of -$350.54 million or -$5.74 per share.
| Cash & Cash Equivalents | 580.21M |
| Total Debt | 930.75M |
| Net Cash | -350.54M |
| Net Cash Per Share | -$5.74 |
| Equity (Book Value) | -220.28M |
| Book Value Per Share | -3.64 |
| Working Capital | 21.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$193.73 million and capital expenditures -$6.96 million, giving a free cash flow of -$196.67 million.
| Operating Cash Flow | -193.73M |
| Capital Expenditures | -6.96M |
| Free Cash Flow | -196.67M |
| FCF Per Share | -$3.22 |
Full Cash Flow StatementMargins
Gross margin is 84.88%, with operating and profit margins of -51.66% and -55.25%.
| Gross Margin | 84.88% |
| Operating Margin | -51.66% |
| Pretax Margin | -53.82% |
| Profit Margin | -55.25% |
| EBITDA Margin | -50.66% |
| EBIT Margin | -51.66% |
| FCF Margin | n/a |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.73% |
| Shareholder Yield | -4.73% |
| Earnings Yield | -2.59% |
| FCF Yield | -1.60% |
Dividend DetailsAnalyst Forecast
The average price target for Ascendis Pharma is $245.76, which is 22.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $245.76 |
| Price Target Difference | 22.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (5Y) | 52.75% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of -0.07 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.07 |
| Piotroski F-Score | 3 |
